Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026

Group 1: Company Overview - Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic CAR T cell products for cancer and autoimmune diseases [4] Group 2: Lead Program and Trials - The lead program, cemacabtagene ansegedleucel (cema-cel), is on track in the pivotal Phase 2 ALPHA3 trial for first-line consolidation in large B-cell lymphoma [1] - The ALPHA3 trial is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, enrolling at over 60 clinical trial sites globally [2] - An interim futility analysis is scheduled for April 2026 to compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation [2] Group 3: Progress in Autoimmune Disease - The company is advancing its ALLO-329 candidate, a dual CD19/CD70 AlloCAR T therapy, utilizing Dagger technology to potentially eliminate conventional lymphodepletion [3] - The Phase 1 RESOLUTION basket trial for ALLO-329 is currently enrolling in dose escalation across various indications, with initial data expected in June 2026 [3]